Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

PITTSBURGH, Oct. 26, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2011.

Financial Highlights

  • Adjusted diluted EPS of $0.55 for the three months ended September 30 compared to $0.43 for the same prior year period;
  • Adjusted diluted EPS of $1.51 for the nine months ended September 30 compared to $1.16 for the same prior year period;
  • Total revenues of $1.58 billion for the three months ended September 30 compared to $1.36 billion for the same prior year period;  
  • Total revenues of $4.60 billion for the nine months ended September 30 compared to $4.02 billion for the same prior year period;  
  • On a GAAP basis, diluted EPS of $0.36 for the three months ended September 30 compared to $0.33 for the same prior year period;
  • On a GAAP basis, diluted EPS of $0.92 for the nine months ended September 30 compared to $0.71 for the same prior year period;
  • Cash provided by operating activities, excluding certain items, was $378.1 million, the highest quarter in terms of the generation of operating cash in the Company's history.

  • Mylan Chairman and CEO Robert J. Coury said: "We have once again delivered a quarter of strong top-line and bottom-line growth, a continued testament to the scale and diversity of our powerful global platform. I would like to note in particular the very impressive results of our specialty segment, Dey Pharma. As a result of strong execution across this business, Dey's performance is accelerating and it continues to be an important and exciting asset and growth driver for Mylan—one which we will continue to build on in the future."

    Coury continued: "We continually demonstrate that Mylan is much more than any one product or any single geography and have repeatedly absorbed the volatility
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
    2. Life Technologies Announces Third Quarter 2011 Results
    3. Insmed to Host 2011 Third Quarter Earnings Conference Call
    4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
    5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
    6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
    7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
    8. HeartWare Schedules Third Quarter Conference Call and Webcast
    9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
    10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
    11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
    (Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
    (Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... identification solutions, today announced its GHS Label Guide . To align chemical ... System (GHS), this guide includes explanations of label components, an example of an ...
    (Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
    Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
    ... Mich., April 15 GeneGo, Inc., the leading,systems ... Science Institute has joined the MetaMiner Cardiac,Consortium. The ... first systems,biology and pathway analysis platform for cardiovascular ... on deliverables that will include,disease specific pathway maps ...
    ... April 15 WallSt.net,s 3-Minute Press Show is,a ... Tolentino., Shows air Monday through Friday on:, ... Show features in-depth interviews with,public company executives on ... is designed to provide viewers with insight into ...
    ... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... therapy and oncology, today reported the completion of ... its Phase 3 program,in benign prostatic hyperplasia (BPH), ... product candidate, cetrorelix. The study,involves approximately 600 patients ...
    Cached Biology Technology:The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: NPHC, PECD, PNRR 2Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: NPHC, PECD, PNRR 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4
    (Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
    (Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
    (Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
    Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
    ... Conservancy (WPC) scientists have discovered a plant in Erie County ... dwarf scouring rush, was identified with the aid of a ... Girard. Dwarf scouring rush is known to exist in ... not been identified in Pennsylvania until this discovery. WPC scientists ...
    ... The Potato Genome Sequencing Consortium (PGSC), an international ... countries, has released a draft sequence of the potato ... Richard Veilleux, professor of horticulture in the College ... a unique phureja type of potato variety that accelerated ...
    ... Investigators at Burnham Institute for Medical Research (Burnham), University ... Research Institute (TSRI), Genomics Institute of the Novartis Research ... model, including three dimensional protein structures, of the central ... ( T. maritima ). This is the first time ...
    Cached Biology News:Erie County home to plant never before recorded in Pa. 2Draft potato genome based on unique potato variety 2Comprehensive understanding of bacteria could lead to new insights into many organisms 2
    Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
    ... The ProteomeLab PF 2D is an automated, ... complex protein mixtures. Part of Beckman ... 2D produces results in just hours. ... proteins present in cell lysates, addressing a ...
    ... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
    ... 295 ex can measure three fluorescence lifetimespicoseconds ... a few minutes. To match the absorption ... tryptophan, the Protein 295 exs excitation source ... emitting 295 nm. Fluorescence of tryptophan is ...
    Biology Products: